Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

Official title

An Exploratory Study on the Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

Overview

To explore the minimum power and frequency of Repeated Low-level Red-light (RLRL) to control myopia progression in low-myopic children aged 8-10 years, and the rebound effect of low-myopic children after discontinuation of RLRL with different combinations of power and frequency.

Detailed description

Myopia has emerged as a significant public health concern in East Asia. The excessive elongation of the axial length ( AL)of the eye, particularly as myopia progresses to high myopia, is associated with mechanical stretching and thinning of the choroid and sclera. This can lead to vision-threatening complications such as myopic macular degeneration, macular hemorrhage, retinal detachment, cataracts, and glaucoma. Given the serious consequences of high myopia and its associated complications, early and effective prevention and control of myopia become a primary focus in safeguarding visual health and enhancing quality of life.

In recent years, RLRL holds significant potential as an effective strategy for preventing and controlling myopia in children and adolescents. However, recent researches prompt further questions: Is the current power of RLRL exposure optimal? Can the frequency of exposure be refined? What is the relationship among exposure power, frequency and myopia control? To explore these questions and clarify the effects of various combinations of exposure power and frequency on myopia progression following RLRL therapy, our research group plans to conduct a prospective, double-blind, single-center, randomized controlled clinical trial. This study aims to provide more comprehensive evidence to support this innovative intervention on myopia prevention and control.

Interventions

• Device Repeated Low-level Red-light
  In addition to single vision spectacle lenses (SVS) with power for correcting distance refraction, the subjects used the prescribed power low-intensity red light treatment instrument for the prescribed number of treatments from Monday to Friday, with a 3-minute interval of 4 hours.
• Device Red LED
  In addition to SVS with power for correcting distance refraction, red LED will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.

Primary outcome measures

• The incidence (%) of axial length increase ≤0.05mm after red light for 3 months measured by the IOL master [Time frame: 1 week, 1, 2, 3 months]

Secondary outcome measures (8)

• The incidence rates (%) of cycloplegic spherical equivalent refraction progressing ≥0.00 D after red light for 3 months measured by the autorefractor [Time frame: 1 week, 1, 2, 3 months]
• Changes of axial length (mm) after discontinuation of red light for 1 months measured by the IOL master [Time frame: 4 months]
• Changes of cycloplegic spherical equivalent refraction (D) after discontinuation of red light for 1 months measured by the autorefractor [Time frame: 4 months]
• Incidence (%) of self-reported adverse events by the quesionnaire including but not limited to glare, flash blindness, and afterimages [Time frame: 1 week, 1, 2, 3, 4 months]
• Change in visual acuity (logMAR) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart [Time frame: 1 week, 1, 2, 3, 4 months]
• Changes in choroidal thickness (μm) measured by the swept-source optical coherence tomography and optical coherence tomography angiography [Time frame: 1 week, 1, 2, 3, 4 months]
• Changes in the amplitudes of waves (mV) measured by the full-filed electroretinogram [Time frame: 1 week, 1, 2, 3, 4 months]
• Changes in the the latency of waves (ms) measured by the full-filed electroretinogram [Time frame: 1 week, 1, 2, 3, 4 months]

Eligibility criteria

Inclusion criteria

• Age: 8-10 years old
• Low myopia: cycloplegic spherical equivalent refractions (SERs) range from -0.50 (inclusive) to -3.00 diopters (D) and astigmatism less than -2.5 D in either eye.
• signed informed consent and was able to participate in the study

Exclusion criteria

• Secondary myopia, such as a history of retinopathy of prematurity or other neonatal diseases; syndromic myopia with a known genetic disorder or connective tissue disease, such as Stickler syndrome or Marfan syndrome
• Strabismus or other binocular vision abnormalities
• Cloudy refractive media: cloudy cornea, cataract or intraocular lens surgery
• Eye diseases that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc.
• History of refractive surgery, internal eye surgery, laser therapy, vitreous injection, etc.
• diabetes, hypertension and other systemic disorders
• History of use of retinal toxic drugs, such as hydroxychloroquine, etc.
• Use of orthokeratology, atropine, multifocal frame glasses and other myopia control methods; children who are currently receiving atropine, orthokeratology, multifocal frame glasses and other myopia control treatment, can be enrolled after 2 weeks of treatment.
• Other reasons considered unsuitable for inclusion by the study physician, including but not limited to other ocular and systemic disease abnormalities

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

China · 1 center

• Shanghai Eye Disease Prevention & Treatment Center — Shanghai

Identifiers

NCT: NCT06717048 · RLPT-SEPTC-2024

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗